Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

doi:10.1002/ajh.70142

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Effectiveness of Gilteritinib Beyond Second-Line Therapy in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Real-World Multicenter Study of 171 Patients.

American journal of hematology - 1 Jan 2026

Molica Matteo, Miralles Gema, Dillon Richard, Annunziata Mario, Basheer Faisal, Bergua Juan M, Calmet Ferran Vall-Llovera, Campbell Victoria, Cetin Denis, Cimino Gaetano, Ciotti Giulia, Corbingi Andrea, De Fazio Laura, Erol Hasim Atakan, Federico Vincenzo, Gil Cristina, Mutlu Yasa Gul, Malcorra Amaia Balerdi, Mariani Sabrina, Mazzone Carla, Mulè Antonino, Musuraca Gerardo, Khan Anjum, Norata Mariana, O'Nions Jenny, Palumbo Fanny Erika, Papayannidis Cristina, Piccioni Anna Lina, Rubio Maria Teresa Olave, Sanchez-Tovar Jackeline, Serin Istemi, Serrao Alessandra, Sevindik Omur Gokmen, Sucato Giuseppe, Urbano Marina Aurora, Vetro Calogero, Vives Susana, Rossi Marco, Martelli Maria Paola, Montesinos Pau, Othman Jad, Perrone Salvatore

Abstract excerpt

Gilteritinib is a selective FLT3 inhibitor approved for the treatment of relapsed or refractory (R/R) FLT3-mutated acute myeloid leukemia (AML) following ≥ 1 prior line of therapy. However, data on its effectiveness in later-line settings is limited. We conducted a multicenter, retrospective study including 171 adult patients with R/R FLT3-mutated AML who received gilteritinib as third-line or beyond between...

Topics

Humans
fms-Like Tyrosine Kinase 3
Leukemia, Myeloid, Acute
Middle Aged
Female

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Male

Adult

Aged

Aniline Compounds

Retrospective Studies

Mutation

Pyrazines

Recurrence

Treatment Outcome

Young Adult

Protein Kinase Inhibitors

Hematopoietic Stem Cell Transplantation

Sulfonamides

Source

Open in PubMed Open full text

Identifiers

PMID: 41273181
DOI: 10.1002/ajh.70142
PMCID: PMC12669949

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.